The levodopa dose-sparing capacity of pergolide compared with that of bromocriptine in an open-label, crossover study

European Journal of Neurology

Volumn 3, Issue 1, 1996, Pages 44-49

  Boas, J ^a   Worm Petersen, J ^b   Dupont, E ^c   Mikkelsen, B ^d   Wermuth, L ^e  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d NORTH DENMARK REGIONAL HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

bromocriptine; levodopa; Parkinson's disease; pergolide

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; LEVODOPA; PERGOLIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0029995230     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.1996.tb00188.x     Document Type: Article

References (23)

1. Ahlskog JE and Muenter MD (1988) Treatment of Parkinson's disease with pergolide: a double-blind study. Mayo Clinical Proceedings 63, 969-978.
2. Bonnet AM, Serre I, Marconi R et al. (1995) A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine. Movement Disorders, 10, 668-671.
3. Cohen G (1985) Oxidative stress in the nervous system. In: Oxidative Stress (Ed. H. Sies), pp. 383-402. London, Academic Press.
4. Corrodi H, Fuxe K, Hökfelt T, Lidbrink P and Ungerstedt U (1973) Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons (Letter). Journal of Pharmaceutics and Pharmacology, 25, 409-411.
5. Diamond SG, Markham CH and Treciokas LJ (1985) Double-blind trial of pergolide for Parkinson's disease. Neurology 35, 291-295.
6. Fahn S and Elton RL (1987) Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Recent Developments in Parkinson's Disease (Eds S Fahn, SD Marsden, DB Calne and M Goldstein), Vol. 2, pp. 153-163. Florheim Park, NJ, Macmillan Healthcare.
7. Hoehn MM and Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17, 427-442.
8. Jankovic J (1984) Parkinsonian disorders. In: Current Neurology (Ed. SH Appel), Vol. 5, pp. 1-49. New York, Wiley.
9. Jankovic J (1985) Long-term use of dopamine agonists in Parkinson's disease. Clinical Neuropharmacology, 8, 131-140.
10. Jankovic J (1986) Pergolide: short-term and long-term experience in Parkinsons's disease. In: Recent Developments in Parkinson's Disease (Eds S Fahn et al.), pp. 339-345. New York, Raven Press.
11. Jenner P (1993) Altered mitochondrial function, iron metabolism and glutthione levels in Parkinson's disease. Acta Neurologica Scandinavia, 87 (suppl.), 6-13.
12. LeWitt PA, Ward CD, Larsen TA et al. (1983) Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology, 33, 1009-1014.
13. Lieberman Goldstein M, Neophytides A et al. (1982) The use of pergolide, a potent dopamine agonist, in Parkinson's disease. Pharmacology and Therapy, 32, 70-75.
14. Lieberman AN, Goldstein M, Leibowitz M et al. (1984) Long-term treatment with pergolide: decreased efficacy with time. Neurology, 34, 223-226.
15. Olanow CW (1988) Pergolide, parlodel crossover study. Neurology, 38, 314-318.
16. Olanow CW (1992) A rationale for dopamine agonists as primary therapy for Parkinson's disease. Canadian Journal of Neurological Science, 19, 108-112.
17. Olanow CW and Alberts MJ (1987) Double-blind controlled study of pergolide mesylate in the treatment of Parkinson's disease. Clinical Neuropharmacology and Therapy, 34, 223-226.
18. ® in Parkinson's disease. Movement Disorders, 9, 40-47.
19. Pezzoli G, Martignoni E, Pacchetti C et al. (1994) Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Movement Disorders, 9, 431-436.
20. Reches A, Wagner HR, Jackson-Lewis V, Yablonskaya-Alter E and Fahn S (1984) Chronic levodopa or pergolide administration induces down-regulation of dopamine receptors in denervated striatum. Neurology, 34, 1208-1212.
21. Rinne UK (1983) Dopamine agonists as a primary treatment of Parkinson's disease. In: Current Concepts of Parkinsons Disease and Related Disorders (Ed. MD Yahr), pp. 77-90. Amsterdam: Excerpta Medica.
22. Rinne UK (1989) Early dopamine agonist therapy in Parkinson's disease. Movement Disorders, 4, 86-94.
23. Sage JI and Duvoisin RC (1985) Pergolide therapy in Parkinson's disease: a double-blind, placebo-controlled study. Clinical Neuropharmacology, 8, 260-265.